Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Fibroleukin at fault in viral hepatitis.
  • Targeting the tubules.
  • PGE2 in control in the kidney.
  • Del-1 drives angiogenesis.
  • Stem cells hold their breath.
  • Version history
  • Article usage
  • Citations to this article

Advertisement

In this issue Free access | 10.1172/JCI119977

In This Issue

Published July 1, 2003 - More info

Published in Volume 112, Issue 1 on July 1, 2003
J Clin Invest. 2003;112(1):1–1. https://doi.org/10.1172/JCI119977.
© 2003 The American Society for Clinical Investigation
Published July 1, 2003 - Version history
View PDF
Fibroleukin at fault in viral hepatitis.

Fibrin deposition and thrombosis within the microvasculature play a pivotal role in the injury observed in viral hepatitis. Activated endothelial cells and macrophages express procoagulants including a novel prothrombinase, Fgl2/fibroleukin, important for the initiation and localization of fibrin deposition. Philip Marsden and colleagues show (pages 58–66) that mouse knockouts of Fgl2/fibroleukin fail to develop a procoagulant response to infection with hepatitis. In addition, the authors show that in humans with chronic HBV, expression of the Fgl2/fibroleukin gene is high and fibrin is deposited in the livers. Collectively, these studies indicate a critical role for Fgl2/fibroleukin in the pathophysiology of viral hepatitis and suggest that inhibition of this prothrombinase may be important for the treatment of inflammatory diseases not only of the liver but also of other tissues.

Targeting the tubules.

After transplantation of female human kidneys into male recipients, Y chromosome positive cells can be detected in the renal tubule of the transplanted kidney. In these studies, bone marrow–derived cells constitute a minor component of total tubular cell mass. Lloyd Cantley and colleagues now demonstrate (pages 42–49) that following ischemic renal injury in the mouse, bone marrow–derived stem cells home to the injured tubular segment, differentiate into a tubular cell phenotype specific for that tubular segment, and ultimately make up the majority of the cells that repair the necrotic region of the tubule. This paper thus challenges the existing paradigm for repair of acute tubular necrosis and suggests that approaches aimed at bone marrow stem cell propagation and delivery to the kidney should be pursued in attempts to treat this disease.

PGE2 in control in the kidney.

Macula densa (MD) control of renin release is an important regulator of salt and water homeostasis in the kidney, particularly during volume depletion. However, details of the MD-signaling mechanism controlling renin release remained uncertain until János Peti-Peterdi and colleagues developed a novel biosensor tool to measure prostaglandin release from the MD (pages 76–82). This tool allowed direct functional evidence that intact MD cells release prostaglandin E2 (PGE2) through their basolateral membrane in response to low luminal NaCl concentrations. These studies provide the first direct evidence that intact MD cells synthesize and release PGE2 during reduced luminal salt content and suggest that this response is important in the control of renin release and renal vascular resistance during salt deprivation.

Del-1 drives angiogenesis.

The extracellular matrix protein Del-1 is one of several novel ECM proteins that accumulate around angiogenic blood vessels in embryonic and tumor tissue and promote angiogenesis in the absence of exogenous growth factors. Judith Varner and colleagues use Del-1 to enhance vessel development and accelerate functional recovery in two models of ischemic myopathy (pages 30–41). Del-1 binds to the integrin αvβ5 on endothelial cells and induces the transcription factor Hox D3, which then serves as a master regulator of subsequent steps in angiogenesis, including induction of another receptor for Del-1, the integrin αvβ3. This process can be inhibited by antibodies against either integrin by genetic ablation of the integrin β5 subunit or by antisense mediated reduction in Hox D3 expression. This angiogenic matrix protein Del-1 may be a useful tool for the therapy of ischemic disease.

Stem cells hold their breath.

Bone marrow (BM), hematopoietic stem, and progenitor cells are distributed along an oxygen (O2) gradient, with stem cells residing in the most hypoxic areas and proliferating progenitors found in O2-rich areas. As the reasons for the differential localization are unknown, Guénahel Danet and colleagues have evaluated the functional and molecular responses of human hematopoietic progenitors and stem cells to hypoxia (pages 126–135). The authors demonstrate that short-term culture under hypoxic conditions allows increased expansion of BM cells compared to normoxia, and that this is correlated with a preferential expansion of primitive BM cell subsets and arrest in the G1 phase. In response to hypoxia, HIF-1α protein was stabilized, surface expression of angiogenic receptors was upregulated, and VEGF secretion was increased. These findings suggest the use of low O2 levels could improve the expansion of human BM-repopulating cells.

Version history
  • Version 1 (July 1, 2003): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Fibroleukin at fault in viral hepatitis.
  • Targeting the tubules.
  • PGE2 in control in the kidney.
  • Del-1 drives angiogenesis.
  • Stem cells hold their breath.
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts